Sorafenib-induced hand-foot syndrome in a patient with desmoid fibromatosis

Sorafenib is an oral multikinase inhibitor widely used in the treatment of various solid malignancies and has recently emerged as a therapeutic option for desmoid fibromatosis. Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysesthesia, is a common cutaneous adverse effect associated with sorafenib therapy. Although sorafenib-induced HFS has been well documented in patients with renal cell carcinoma and hepatocellular carcinoma, reports in patients with desmoid fibromatosis (DF) remain limited. We report a case of grade 2 sorafenib-induced HFS in a 21-year-old man receiving sorafenib for DF. Sorafenib continued, and the patient was treated with topical clobetasol propionate 0.05%, salicylic acid 12%, and emollients. Partial clinical improvement was observed after three weeks without dose modification. This case highlights the importance of early recognition and prompt management of sorafenib-induced HFS to ensure treatment adherence and optimize patient outcomes.